Results 41 to 50 of about 3,750,451 (195)

Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2.

Circulation: Arrhythmia and Electrophysiology, 2019
BACKGROUND Oral anticoagulant use is common among patients undergoing pacemaker or defibrillator surgery. BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial; NCT00800137) demonstrated that perioperative warfarin ...
V. Essebag, J. Healey, J. Joza, P. Nery, E. Kalfon, T. Leiria, A. Verma, F. Ayala-Paredes, B. Coutu, G. Sumner, G. Becker, F. Philippon, J. Eikelboom, R. Sandhu, John Sapp, R. Leather, D. Yung, B. Thibault, C. Simpson, K. Ahmad, Satish C. Toal, M. Sturmer, K. Kavanagh, E. Crystal, G. Wells, A. Krahn, D. Birnie   +26 more
semanticscholar   +1 more source

Plant Alkaloids as Antiplatelet Agent: Drugs of Future in the light of recent development

Frontiers in Pharmacology, 2016
The alkaloid is a class of naturally occurring organic nitrogen-containing compounds that are frequently found in the plant kingdom. Many alkaloids are valuable medicinal agents that can be utilized to treat various diseases including malaria, diabetics,
Haroon Khan, Qurrat Ul Ain, Mohammad S Mubarak, Aini Pervaiz   +3 more
doaj   +1 more source

Delayed retropharyngeal hematoma following a minor facial blunt trauma

Trauma Case Reports, 2021
We described the case of 75 years old male patient with an airway obstruction due to retropharyngeal hematoma that developed after a minor blunt trauma to the face. The patient was not taking any anticoagulants or antiplatelet agents and did not have any
Yuya Kitai, Ryota Sato
doaj   +1 more source

Study design of endoscopic polypectomy on clopidogrel (EPOC): A randomised controlled trial

Contemporary Clinical Trials Communications, 2019
Concurrent cardiovascular disease and antiplatelet use (clopidogrel, prasugrel and ticagrelor) use poses a significant peri-endoscopic management challenge with a paucity of high-quality evidence available.
Shara Ket, Andrew Metz, Alan Moss, Ravinder Ogra, William Tam, Robyn Secomb, John Reynolds, Peter R. Gibson, Gregor Brown   +8 more
doaj   +1 more source

The SAFEST Study: Survey on Antiplatelets in Flow Diversion for Aneurysm Endovascular Treatment

Stroke: Vascular and Interventional Neurology
Background Flow diversion has emerged as a promising treatment strategy for intracranial aneurysms, yet the influence of antiplatelet therapy on treatment outcomes remains uncertain. Regional and institutional variability in antiplatelet regimens further
Sophia Hohenstatt, Dominik F. Vollherbst, Thanh N. Nguyen, Zhongrong Miao, Mai Duy Ton, Hiroshi Yamagami, Adam A. Dmytriw, Gabriele Maliandi, Martin Bendszus, Jessica Jesser, Markus A. Möhlenbruch   +10 more
doaj   +1 more source

Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China

Patient Preference and Adherence, 2019
Xin Liu,1 Xiaoning He,1 Jing Wu,1 Da Luo1,2 1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China; 2Tianjin Health Development Research Center, Tianjin, People’s Republic of ...
Liu X, He X, Wu J, Luo D
doaj  

Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease

Biomedicines, 2021
The successful treatment of peripheral arterial disease (PAD) depends on adequate adherence to medications including antiplatelet agents. The aims of this study were (a) to identify the proportion of nonpersistent patients who reinitiated antiplatelet ...
Martin Wawruch, Jan Murin, Tomas Tesar, Martina Paduchova, Miriam Petrova, Denisa Celovska, Beata Havelkova, Michal Trnka, Emma Aarnio   +8 more
doaj   +1 more source

Dual antiplatelet therapy challenges in emergent noncardiac surgeries

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2021
In today's era, patients with coronary stents are presenting for various surgeries while still being on dual antiplatelet therapy. This leads to balancing the risk between myocardial ischemia if therapy is discontinued and bleeding risk due to surgery ...
Rahil Singh, Anisha Singh, Sukhyanti Kerai   +2 more
doaj   +1 more source

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

Cancer Metastasis Review, 2017
The association between coagulation and cancer development has been observed for centuries. However, the connection between inflammation and malignancy is also well-recognized. The plethora of evidence indicates that among multiple hemostasis components,
M. Wojtukiewicz, D. Hempel, E. Sierko, S. Tucker, K. Honn   +4 more
semanticscholar   +1 more source

The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data

Korean Circulation Journal, 2017
Background and Objectives Despite the favorable efficacy of new antiplatelet agents demonstrated in randomized controlled trials, their clinical implications in Korea are unclear.
Choongki Kim, D. Shin, C. Ahn, Jung‐Sun Kim, Byeong‐Keuk Kim, Y. Ko, D. Choi, M. Hong, Ju-Heon Park, H. Lee, Y. Choi, Young Choi, Sang-Kwon Oh, Y. Jang   +13 more
semanticscholar   +1 more source